First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple cancers

Share this post

A phase I, first-in-human study reveals for the first time, an investigational drug that is effective and safe for patients with cancers caused by an alteration in the receptor tyrosine kinase known as RET. The drug appears to be promising as a potential therapy for RET-driven cancers, such as medullary and papillary thyroid, non-small cell lung, colorectal and bile duct cancers, which have been historically difficult to treat.

This post was syndicated from Top Health News -- ScienceDaily. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply